Kancera AB (Sweden) Today
| KAN Stock | SEK 1.10 0.04 3.77% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Kancera AB is selling for under 1.10 as of the 26th of November 2024; that is 3.77% up since the beginning of the trading day. The stock's last reported lowest price was 1.05. Kancera AB has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Kancera AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.. The company has 79.53 M outstanding shares. More on Kancera AB
Moving together with Kancera Stock
| 0.83 | CAMX | Camurus AB | PairCorr |
| 0.92 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.87 | NANOFS | Nanoform Finland Plc | PairCorr |
Moving against Kancera Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Kancera Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Kancera AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kancera AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Kancera AB (KAN) is traded on Stockholm Exchange in Sweden and employs 5 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 262.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kancera AB's market, we take the total number of its shares issued and multiply it by Kancera AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kancera AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 79.53 M outstanding shares.
Kancera AB has accumulated about 106.52 M in cash with (44.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check Kancera AB Probability Of Bankruptcy
Ownership AllocationKancera AB maintains a total of 79.53 Million outstanding shares. Kancera AB secures 13.72 % of its outstanding shares held by insiders and 2.86 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kancera Ownership Details
Kancera AB Risk Profiles
Although Kancera AB's alpha and beta are two of the key measurements used to evaluate Kancera AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.21 | |||
| Standard Deviation | 7.97 | |||
| Variance | 63.56 | |||
| Risk Adjusted Performance | (0.07) |
Kancera Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Kancera AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Kancera AB Corporate Management
Elected by the shareholders, the Kancera AB's board of directors comprises two types of representatives: Kancera AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kancera. The board's role is to monitor Kancera AB's management team and ensure that shareholders' interests are well served. Kancera AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kancera AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Olin | CEO Director | Profile | |
| Martin Norin | Chief Officer | Profile | |
| Hans Richter | Chief Officer | Profile | |
| Peter Selin | Exec Devel | Profile | |
| Niclas Brynne | Head Devel | Profile | |
| Torbjrn Lundstrm | Chief Officer | Profile |
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.